Economic and humanistic burden associated with depression and anxiety among adults with non‐communicable chronic diseases (NCCDs) in the United States
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Patients with both major depressive disorder (MDD) and generalized anxiety disorder (GAD) in addition to one or multiple comorbid non-communicable chronic diseases (NCCDs) face unique challenges. However, few studies have characterized how the burden of co-occurring MDD and GAD differs from that of only MDD or only GAD among patients with NCCDs. METHODS: In this study, we used Medical Expenditures Panel Survey data from 2010-2017 to understand how the economic and humanistic burden of co-occurring MDD and GAD differs from that of MDD or GAD alone among patients with NCCDs. We used generalized linear models to investigate this relationship and controlled for patient sociodemographics and clinical characteristics. RESULTS: Co-occurring MDD and GAD was associated with increases in mean annual per patient inpatient visits, office visits, emergency department visits, annual drug costs, and total medical costs. Among patients with 3+ NCCDs, MDD or GAD only was associated with lower odds ratios (ORs) of limitations in activities of daily living (ADLs; 0.532 and 0.508, respectively) and social (0.503, 0.526) and physical limitations (0.613, 0.613) compared to co-occurring MDD and GAD. Compared to patients with co-occurring MDD and GAD, having MDD only or GAD only was associated with significantly lower odds of cognitive limitations (0.659 and 0.461, respectively) in patients with 1-2 NCCDs and patients with 3+ NCCDs (0.511, 0.416). DISCUSSION: Comorbid MDD and GAD was associated with higher economic burden, lower quality of life, and greater limitations in daily living compared to MDD or GAD alone. Health-related economic and humanistic burden increased with number of NCCDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Nishita, M., Park, S.-Y., Nishio, T., Kamizaki, K., Wang, Z., Tamada, K., Takumi, T., Hashimoto, R., Otani, H., Pazour, G. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-016-0028-x · Cited by 15,947
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60240-2 · Cited by 6,972 · cited 3×
“3 million adults in the United States (US).(8,9) A causal relationship has been shown not only between NCCDs increasing the likelihood of developing MDD or GAD, but also MDD or GAD increasing the likelihood of developing NCCDs.”
BackgroundDiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.629 · Cited by 2,695
Collaborative Care for Depression: A Cumulative Meta-analysis and Review of Longer-term Outcomes
Gilbody, S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2314 · Cited by 1,340
Katon, W. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00273-7 · Cited by 1,223
Relationship of Depression and Diabetes Self-Care, Medication Adherence, and Preventive Care
Lin, E. H. B., Katon, W., Von Korff, M., Rutter, C., Simon, G. E., Oliver, M., Ciechanowski, P., Ludman, E. J., Bush, T., & Young, B. (2004) · Diabetes Care · doi:10.2337/diacare.27.9.2154 · Cited by 1,146 · cited 1×
“The presence of MDD and/or GAD can complicate the course of NCCDs by causing increased inflammation, unhealthy lifestyles, and poor adherence to treatment.(12) Comorbid medical and mental conditions increase symptom burden, decrease length and quality of life, and elevate medical costs.”
BackgroundExamining a Bidirectional Association Between Depressive Symptoms and Diabetes
Golden, S. H. (2008) · JAMA · doi:10.1001/jama.299.23.2751 · Cited by 893 · cited 12×
“Furthermore, research has shown that treating comorbid MDD and GAD is more challenging than managing either condition alone.16 In this study, we used Medical Expenditures Panel Survey (MEPS) data to determine how the economic and humanistic burden of co-occurring MDD and GAD differs from that of only MDD or only GAD a…”
BackgroundInfluentialEgede, L. E. (2007) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.06.002 · Cited by 637
Increased Medical Costs of a Population-Based Sample of Depressed Elderly Patients
Katon, W. J., Lin, E., Russo, J., & Unützer, J. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.9.897 · Cited by 504
Research works printed but not linked: 3
- 2005, Computing Standard Errors for MEPS Estimates
- 2009, Year Book of Psychiatry & Applied Mental Health
- Melek S, Norris D Chronic conditions and comorbid psychological disorders. Paper presented at: Journal Of Mental Health Policy And Economics; 2011.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSingle Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial
Robison, R. J., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Jemison, J., Karas, S. M., Karlin, D. R., Solomon, T. M., et al. (2025) · JAMA · doi:10.1001/jama.2025.13481 · Cited by 53
mTORC1 Signaling Pathway Mediates Chronic Stress-Induced Synapse Loss in the Hippocampus
Luo, Y., Ye, X., Fang, Y.-Z., Li, M., Xia, Z., Liu, J., Lin, X., Huang, Z., Zhu, X.-Q., Huang, J.-J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.801234 · Cited by 39
“Major depressive disorder (MDD) is one of the most common neuropsychiatric disorders characterized by low mood, hopelessness and suicidality, which seriously threatens human health and leads to heavy socioeconomic burdens (Simon, 2003; Armbrecht et al., 2021).”
BackgroundAdair, M., Christensen, M. C., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.074 · Cited by 31
Abbas, U., Hussain, N., Tanveer, M., Laghari, R. N., Ahmed, I., & Rajper, A. B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323126 · Cited by 32
“The chronic nature of these conditions, coupled with the burden of ongoing management and potential complications, contributes to these elevated levels of depression [26,27].”
Reangsing, C., Trakooltorwong, P., Maneekunwong, K., Thepsaw, J., & Oerther, S. E. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04102-9 · Cited by 35
“Moreover, having anxiety disorder was associated with a low quality of life [16], and a lot of limitation in daily living such as social restriction [17].”
BackgroundThe Search for Consistency in Residual Symptoms in Major Depressive Disorder: A Narrative Review
Pastuszak, M., Cubała, W. J., Kwaśny, A., & Mechlińska, A. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080828 · Cited by 18
“The public health implications stem from the well-established link between MDD and several common chronic physical diseases [3,4].”
BackgroundAlmeida, S. S., Christensen, M. C., Simonsen, K., & Adair, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221132468 · Cited by 7
“In addition, MDD and co-morbid GAD are linked to a lower health-related quality of life (HRQoL), increased functional and cognitive impairment, and greater limitations in daily activities, than observed with either disorder alone (Armbrecht et al., 2021; Zhou et al., 2017).”
BackgroundYuan, Y., Hou, P., Wang, S., Kitayama, A., Yanagihara, K., & Liang, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1239445 · Cited by 9
Xie, X., Yu, X., Zhang, H., Dai, H., Huang, Y., & Wu, F. (2024) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.08.009 · Cited by 5
Cardoner, N., Gutiérrez-Rojas, L., Sáiz, P. A., Lahera, G., Álvarez-Mon, M. Á., Ortega, P. A., & Pérez‐Páramo, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1483770 · Cited by 8
Fan, M., Li, L., Xu, X., Zhou, C., Wang, P., Yin, W., Pei, W., & Wang, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-45401-y · Cited by 5
“Although paroxetine does not have a direct effect on sleep, our results have shown that the sleep quality of the study group has also improved with the alleviation of depressive and anxiety symptoms.”
BackgroundResultThe effect of GLP-1 receptor agonists on anxiety: A systematic review
Yi, Y. T., Zheng, Y. J., Bargiota, S. I., Dri, C. E., Teopiz, K. M., Wong, S., Le, G. H., Kwan, A. T. H., Cao, B., Ho, R., et al. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107844 · Cited by 5
Self-citationOluboka, O. J., Habert, J., Khullar, A., Robinson, D. J., Katzman, M. A., Klassen, L. J., Soares, C., Chokka, P. R., Oakander, M. A., McIntyre, R. S., et al. (2025) · CNS Spectrums · doi:10.1017/s1092852925000276 · Cited by 3
“18,94,96,97 Individuals with more severe baseline anxiety may be less responsive to MDD treatment.”
Self-citationLi, X., Zheng, S., Feng, Z., Liu, X., Ding, Y., Zhang, L., Zhang, G., Liu, M., Zhu, H., & Jia, H. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2301064 · Cited by 3
“Its profound impact on the patient’s quality of life, social functioning and its significant economic burden cannot be overlooked (Konnopka and König 2020; Armbrecht et al. 2021).”
BackgroundFerries, E., Suponcic, S., Louie, D. J., Robinson, K., Lam, F., Silber, A., O’Hara, M., Duong, P., McIntyre, R. S., & Strawn, J. R. (2026) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2026.100172 · Cited by 5
Self-citationAlmasi, S., Mohammadi, H., & Vatandost, S. (2022) · Journal of Health and Care · doi:10.52547/jhc.23.4.313 · Cited by 2
Shimokhina, N. Y., Baranovich, Z. R., Yunevich, A. S., Савченко, А. А., Zimnitskaya, O. V., & Петрова, М. М. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-2-101-108 · Cited by 2
Treatment resistant depression in electronic health records: definitions matter
Iveson, M. H., Ball, E. L., Lo, C. W. H., Falis, M., Lewis, C. M., & Whalley, H. C. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08085-y · Cited by 5
“…Treatment Resistant Depression (TRD), occurs in around a third of patients [31, 37] and can have severe consequences for health and wellbeing [2, 14, 20–22 , Although defined in clinical trials using validated scale scores (e.g., Montgomery-Asberg Depression Rating Scale), TRD is harder to…”
Duong, P., Mojtabai, R., Ferries, E., Suponcic, S., Finlayson, K., Li, V. W., Chen, N., Maculaitis, M. C., & Karlin, D. R. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120972 · Cited by 4
Nascimento, M. D. M., Marques, A., Gouveia, É. R., Ferrari, G., & Ihle, A. (2025) · Psychiatric Quarterly · doi:10.1007/s11126-025-10147-5
“The results can guide current European health surveillance policies to reduce the burden of mental disorders and cognitive deficits during aging [ 58, 59].”
Belova, A., Munson, K., Keeler, D. G., Sluder, M., Kiesel, A., Sarofim, M. C., Silva, R., Anenberg, S. C., Clayton, S., & Gould, C. A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5261619
Zhang, W., Yang, K., Zhai, Y.-C., Miao, Q.-S., & Cui, Y. (2025) · World Journal of Psychiatry · doi:10.5498/wjp.v15.i12.112122 · Cited by 1
Reangsing, C., Trakooltorwong, P., Maneekunwong, K., Thepsaw, J., & Oerther, S. E. (2023) · Figshare · doi:10.6084/m9.figshare.23803102
Metadata
- Authors
- Armbrecht, E., Shah, R., Poorman, G. W., Luo, L., Stephens, J. M., Li, B., Pappadopulos, E., Haider, S., & McIntyre, R. S.
- Affiliations
- Saint Louis University (US)
- Pharmerit (United States) (US)
- Pfizer (United States) (US)
- Viatris (US)
- University Health Network (CA)
- Corresponding author
- Stephens, Jennifer M
- ORCID
- Venue
- Journal of Multidisciplinary Healthcare
- Publisher
- Informa UK Limited
- Published
- 2021-04
- Volume
- Volume 14
- Pages
- 887-896
- ISSN
- 1178-2390 (ISSN-L)
- PMC
- PMC8079356
- OpenAlex
- W3156276376
- Cited by
- 24
- References
- 27
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 2 · 2021: 1
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Multidisciplinary Healthcare (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- major depressive disorder, generalized anxiety disorder, comorbidities, non-communicable diseases, economic burden, humanistic burden, quality of life, activities of daily living, health care costs, health care utilization, cognitive limitations, polypharmacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.